Incretin Therapies in the Management of Elderly Patients with Type 2 Diabetes Mellitus

References

• . Sloan FA, Bethel MA, Ruiz D Jr, Shea AM, Feinglos MN. The growing burden of diabetes mellitus in the US elderly population. Arch Intern Med. 2008;168(2):192–199
   PubMedGoogle Scholar
• . Fagot-Campagna A, Bourdel-Marchasson I, Simon D. Burden of diabetes in an aging population: prevalence, incidence, mortality, characteristics and quality of care. Diabetes Metab. 2005;31(spec no 2): 5S35–5S52
   Google Scholar
• . Selvin E, Coresh J, Brancati FL. The burden and treatment of diabetes in elderly individuals in the U.S. Diabetes Care. 2006;29(11): 2415–2419
   PubMed Web of Science ®Google Scholar
• . Bourdel-Marchasson I, Berrut G. Caring the elderly diabetic patient with respect to concepts of successful aging and frailty. Diabetes Metab. 2005;31(spec no 2):5S13–5S19
   Google Scholar
• . Abbatecola AM, Paolisso G, Corsonello A, Bustacchini S, Lattanzio F. Antidiabetic oral treatment in older people: does frailty matter? Drugs Aging. 2009;26( suppl 1):53–62
   PubMedGoogle Scholar
• . Bourdel Marchasson I, Doucet J, Bauduceau B, ; ALFEDIAM/SFGG French-Speaking Group for Study of Diabetes in the Elderly. Key priorities in managing glucose control in older people with diabetes. J Nutr Health Aging. 2009;13(8):685–691
   PubMedGoogle Scholar
• . Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25(3):245–254
   PubMed Web of Science ®Google Scholar
• . Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging. 2004;21(8):511–530
   PubMed Web of Science ®Google Scholar
• . Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging. 2008;25(11):913–925
   PubMed Web of Science ®Google Scholar
• . Mathieu C, Bollaerts K. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract Suppl. 2007;(154):29–37
   Google Scholar
• . Heller S, Chapman J, McCloud J, Ward J. Unreliability of reports of hypoglycaemia by diabetic patients. BMJ. 1995;310(6977):440
   Google Scholar
• . Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns. 2007;68(1):10–15
   PubMed Web of Science ®Google Scholar
• . Lassmann-Vague V. Hypoglycaemia in elderly diabetic patients. Diabetes Metab. 2005;31(spec no 2):5S53–5S57
   Google Scholar
• . Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab. 2008;10( suppl 1):25–32
   PubMed Web of Science ®Google Scholar
• . Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32(8):1513–1517
   PubMed Web of Science ®Google Scholar
• . Miller ME, Bonds DE, Gerstein HC, ; ACCORD Investigators. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010;340:b5444
   PubMed Web of Science ®Google Scholar
• . Skyler JS, Bergenstal R, Bonow RO, ; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119(2):351–357
   PubMed Web of Science ®Google Scholar
• . Bonds DE, Miller ME, Bergenstal RM, . The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909
   PubMed Web of Science ®Google Scholar
• . Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301(15):1565–1572
   PubMed Web of Science ®Google Scholar
• . Barnett AH. Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy. Curr Med Res Opin. 2010;26(6):1333–1342
   PubMed Web of Science ®Google Scholar
• . Cohen DL, Neil HA, Thorogood M, Mann JI. A population-based study of the incidence of complications associated with type 2 diabetes in the elderly. Diabet Med. 1991;8(10):928–933
   Google Scholar
• . Sinclair AJ, Robert IE, Croxson SC. Mortality in older people with diabetes mellitus. Diabet Med. 1997;14(8):639–647
   Google Scholar
• . Volpato S, Maraldi C, Fellin R. Type 2 diabetes and risk for functional decline and disability in older persons. Curr Diabetes Rev. 2010;6(3):134–143
   PubMedGoogle Scholar
• . Bourdel-Marchasson I, Helmer C, Fagot-Campagna A, Dehail P, Joseph PA. Disability and quality of life in elderly people with diabetes. Diabetes Metab. 2007;33( suppl 1):S66–S74
   Google Scholar
• . Kalyani RR, Saudek CD, Brancati FL, Selvin E. Association of diabetes, comorbidities, and A1c with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999–2006. Diabetes Care. 2010;33(5): 1055–1060
   PubMed Web of Science ®Google Scholar
• . Park SW, Goodpaster BH, Strotmeyer ES, ; Health, Aging, and Body Composition Study. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care. 2007;30(6):1507–1512
   PubMed Web of Science ®Google Scholar
• . Munshi M, Grande L, Hayes M, . Cognitive dysfunction is associated with poor diabetes control in older adults. Diabetes Care. 2006;29(8):1794–1799
   PubMed Web of Science ®Google Scholar
• . Fontbonne A, Berr C, Ducimetière P, Alpérovitch A. Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabetes Care. 2001;24(2):366–370
   PubMed Web of Science ®Google Scholar
• . Solanki RK, Dubey V, Munshi D. Neurocognitive impairment and comorbid depression in patients of diabetes mellitus. Int J Diabetes Dev Ctries. 2009;29(3):133–138
   Google Scholar
• . Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589
   PubMed Web of Science ®Google Scholar
• . Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MW. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care. 2006;29(2): 345–351
   PubMedGoogle Scholar
• . Doucet J, Le Floch JP, Bauduceau B, Verny C. What is the relationship between blood sugar and the morbidity and mortality at 5 years of type 2 diabetics aged 70 and over: GERODIAB project. Diabetes Metab. 2009;35:A49
   PubMed Web of Science ®Google Scholar
• . Holstein A, Stumvoll M. Contraindications can damage your health—is metformin a case in point? Diabetologia. 2005;48(12):2454–2459
   Google Scholar
• . Tahrani AA, Varughese GI, Scarpello JH, Hanna FW. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ. 2007;335(7618):508–512
   PubMed Web of Science ®Google Scholar
• . Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med. 2007;24(10):1160–1163
   Google Scholar
• . Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010;33(2):322–326
   PubMed Web of Science ®Google Scholar
• . Papanas N, Maltezos E, Mikhailidis DP. Metformin and cancer: licence to heal? Expert Opin Investig Drugs. 2010;19(8):913–917
   PubMed Web of Science ®Google Scholar
• . Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2001;17(6):467–473
   PubMed Web of Science ®Google Scholar
• . Cryer PE. Severe iatrogenic hypoglycemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2007;3(1):4–5
   Google Scholar
• . Doucet J. Use of antidiabetic drugs in elderly patients. Diabetes Metab. 2005;31(spec no 2):5S98–5S104
   Google Scholar
• . Josse RG, Chiasson JL, Ryan EA, . Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract. 2003;59(1):37–42
   PubMed Web of Science ®Google Scholar
• . Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol. 2009;147(4):583–586
   PubMed Web of Science ®Google Scholar
• . Schwartz AV, Sellmeyer DE, Vittinghoff E, . Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91(9):3349–3354
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Wolski K. Rosiglitazone Revisited: An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality [published online ahead of print June 28, 2010]. Arch Intern Med
   Google Scholar
• . Jover N, Traissac T, Pinganaud G, Moras JB, Rainfray M, Bourdel-Marchasson I. Varying insulin use in older hospitalized patients with diabetes. J Nutr Health Aging. 2009;13(5):456–459
   PubMedGoogle Scholar
• . Moghissi ES, Korytkowski MT, DiNardo M, ; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–1131
   PubMed Web of Science ®Google Scholar
• . Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med. 2007;35(10):2262–2267
   PubMed Web of Science ®Google Scholar
• . Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705
   PubMed Web of Science ®Google Scholar
• . Meneilly GS, Veldhuis JD, Elahi D. Deconvolution analysis of rapid insulin pulses before and after six weeks of continuous subcutaneous administration of glucagon-like peptide-1 in elderly patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90(11):6251–6256
   PubMedGoogle Scholar
• . Nauck MA, Heimesaat MM, Behle K, . Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239–1246
   PubMed Web of Science ®Google Scholar
• . Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care. 2003;26(10):2835–2841
   PubMed Web of Science ®Google Scholar
• . Gallwitz B. Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus. Drug Saf. 2010;33(2):87–100
   Google Scholar
• . Byetta [package insert]. San Diego, CA: Eli Lilly and Co; 2010. http://pi.lilly.com/us/byetta-pi.pdf. Accessed January 12, 2011
   Google Scholar
• . European Medicines Agency. Byetta EPAR summary for the public. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000698/WC500051840.pdf. Updated August 2008. Accessed January 12, 2011
   Google Scholar
• . Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–2635
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–1100
   PubMed Web of Science ®Google Scholar
• . Kendall DM, Riddle MC, Rosenstock J, . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083–1091
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Duran S, Kim D, . A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50(2):259–267
   PubMed Web of Science ®Google Scholar
• . Zinman B, Hoogwerf BJ, Durán García S, . The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146(7):477–485
   PubMed Web of Science ®Google Scholar
• . Drucker DJ, Buse JB, Taylor K, ; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250
   PubMed Web of Science ®Google Scholar
• . Croom KF, McCormack PL. Liraglutide: a review of its use in type 2 diabetes mellitus. Drugs. 2009;69(14):1985–2004
   PubMed Web of Science ®Google Scholar
• . Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analog liraglutide. Br J Clin Pharmacol. 2009;68(6):898–905
   PubMed Web of Science ®Google Scholar
• . Buse JB, Rosenstock J, Sesti G, ; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47
   PubMed Web of Science ®Google Scholar
• . Garber A, Henry R, Ratner R, ; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–481
   PubMed Web of Science ®Google Scholar
• . Marre M, Shaw J, Brändle M, ; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analog, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–278
   PubMed Web of Science ®Google Scholar
• . Nauck M, Frid A, Hermansen K, ; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90
   PubMed Web of Science ®Google Scholar
• . Russell-Jones D, Vaag A, Schmitz O, ; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046–2055
   PubMed Web of Science ®Google Scholar
• . Zinman B, Gerich J, Buse JB, ; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32(7):1224–1230
   PubMed Web of Science ®Google Scholar
• . Liraglutide [package insert]. Bagsværd, Denmark: Novo Nordisk; 2010. http://www.medicines.org.uk/emc/medicine/21986/SPC/. Accessed January 12, 2011
   Google Scholar
• . Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010;70(4):489–512
   PubMedGoogle Scholar
• . Barzilai N, Mahoney EM, Guo H, . Sitagliptin is well tolerated and leads to rapid improvement in blood glucose in the first days of monotherapy in patients aged 65 years and older with T2DM. Diabetes. 2009;58( suppl 1):A158
   Google Scholar
• . Williams-Herman D, Swern AS, Davies MJ, Katzeff HL, Stein PP. In patients with type 2 diabetes, sitagliptin effectively lowers A1c regardless of patient age, gender, or body mass index. Diabetes. 2008;57( suppl 1):A148
   Google Scholar
• . Chan JC, Scott R, Arjona Ferreira JC, . Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10(7):545–555
   PubMed Web of Science ®Google Scholar
• . Williams-Herman D, Engel SS, Round E, . Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7
   PubMed Web of Science ®Google Scholar
• . ClinicalTrials.gov. Sitagliptin in the elderly. http://clinicaltrials.gov/ct2/show/NCT00451113. Updated September 23, 2010. Accessed January 12, 2011. NCT00451113
   Google Scholar
• . ClinicalTrials.gov. Safety and efficacy of sitagliptin compared with glimepiride in elderly patients with type 2 diabetes mellitus (0431–251). http://clinicaltrials.gov/ct2/show/NCT01189890. Updated December 22, 2010. Accessed January 12, 2011. NCT01189890
   Google Scholar
• . ClinicalTrials.gov. Study of sitagliptin in older type 2 diabetics. http://clinicaltrials.gov/ct2/show/NCT00305604. Updated April 20, 2010. Accessed January 12, 2011. NCT00305604
   Google Scholar
• . Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs. 2010;70(16):2089–2112
   PubMed Web of Science ®Google Scholar
• . ClinicalTrials.gov. Safety and tolerability of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiency. http://clinicaltrials.gov/ct2/show/NCT00646542. Updated May 6, 2010. Accessed January 12, 2011. NCT00646542
   Google Scholar
• . ClinicalTrials.gov. Safety and tolerability of vildagliptin versus sitagliptin in patients with type 2 diabetes and severe renal insufficiency. http://clinicaltrials.gov/ct2/show/NCT00616811. Updated May 6, 2010. Accessed January 12, 2011. NCT00616811
   Google Scholar
• . Pratley RE, Rosenstock J, Pi-Sunyer FX, . Management of type 2 diabetes in treatment-naïve elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care. 2007;30(12):3017–3022
   PubMed Web of Science ®Google Scholar
• . Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab. 2009;11(8):804–812
   PubMed Web of Science ®Google Scholar
• . Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥ 75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab. 2011;13(1):55–64
   PubMed Web of Science ®Google Scholar
• . Scherbaum WA, Schweizer A, Mari A, . Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*. Diabetes Obes Metab. 2008;10(8):675–682
   PubMed Web of Science ®Google Scholar
• . Scherbaum WA, Schweizer A, Mari A, . Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008;10(11):1114–1124
   Google Scholar
• . Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50(6):1148–1155
   PubMed Web of Science ®Google Scholar
• . Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res. 2008;40(6):427–430
   PubMedGoogle Scholar
• . Ferrannini E, Fonseca V, Zinman B, . Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157–166
   PubMed Web of Science ®Google Scholar
• . Matthews DR, Dejager S, Ahren B, . Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780–789
   PubMed Web of Science ®Google Scholar
• . Ahrén B, Schweizer A, Dejager S, . Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(4):1236–1243
   PubMed Web of Science ®Google Scholar
• . Billiones R. Saxagliptin in type 2 diabetes. Drugs Today (Barc). 2010;46(2):101–108
   Google Scholar
• . Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12(8):648–658
   PubMed Web of Science ®Google Scholar
• . Maheux P, Doucet J, Allen E, . Efficacy and safety of saxagliptin 5 mg once-daily therapy in elderly patients with type 2 diabetes mellitus. Diabetologia. 2009;52( suppl 1):S302
   Google Scholar
• . Frederich R, Alexander JH, Fiedorek FT, . A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122(3):16–27
   PubMed Web of Science ®Google Scholar
• . ClinicalTrials.gov. Saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin (GENERATION). http://clinicaltrials.gov/ct2/show/NCT01006603. Updated January 10, 2011. Accessed January 12, 2011. NCT01006603
   Google Scholar
• . Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010;70(15):2051–2072
   PubMedGoogle Scholar
• . Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009;57(11):2011–2019
   PubMed Web of Science ®Google Scholar
• . ClinicalTrials.gov. Efficacy and safety of alogliptin compared to glipizide in elderly diabetics. http://clinicaltrials.gov/ct2/show/NCT00707993. Updated September 10, 2010. Accessed January 12, 2011. NCT00707993
   Google Scholar
• . Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2010;19(1):133–140
   PubMed Web of Science ®Google Scholar
• . ClinicalTrials.gov. Efficacy and safety of linagliptin in elderly patients with type 2 diabetes. http://clinicaltrials.gov/ct2/show/NCT01084005. Updated December 15, 2010. Accessed January 12, 2011. NCT01084005
   Google Scholar